FDA Approves Generic Version of Painkiller Celebrex
Title: FDA Approves Generic Version of Painkiller CelebrexCategory: Health NewsCreated: 5/30/2014 4:36:00 PMLast Editorial Review: 6/2/2014 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - June 2, 2014 Category: Rheumatology Source Type: news
FDA Approves First Generic Versions of Celecoxib
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 2, 2014 Category: Journals (General) Source Type: news
FDA Approves Generic Celecoxib (FREE)
By the Editors
The FDA has … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - June 2, 2014 Category: Primary Care Source Type: news
Generic Celebrex (celecoxib) Gets FDA OkayGeneric Celebrex (celecoxib) Gets FDA Okay
Teva Pharmaceutical Industries will market capsules in strengths of 50 mg, 100 mg, 200 mg, and 400 mg. Mylan Pharmaceuticals received approval to market a 50-mg capsule. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 31, 2014 Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news
Business Briefing: F.D.A. Approves Celebrex in Generic Versions
The blockbuster drug, known generically as celecoxib, is used to treat pain, rheumatoid arthritis, osteoarthritis and other conditions. (Source: NYT Health)
Source: NYT Health - May 30, 2014 Category: Consumer Health News Authors: By THE ASSOCIATED PRESS Tags: Celebrex (Drug) Pfizer Inc PFE NYSE Food and Drug Administration Generic Brands and Products Mylan Inc MYL NASDAQ Source Type: news
Generic Celecoxib Gets FDA Nod
(MedPage Today) -- The FDA has approved generic versions of the COX-2 selective nonsteroidal anti-inflammatory drug celecoxib, the agency announced today. (Source: MedPage Today Pain Management)
Source: MedPage Today Pain Management - May 30, 2014 Category: Anesthesiology Source Type: news
FDA Approves Generic Version of Painkiller Celebrex
Medicine will carry warning alerting users of potential heart risks (Source: WebMD Health)
Source: WebMD Health - May 30, 2014 Category: Consumer Health News Source Type: news
FDA approves first generic versions of celecoxib
The U.S. Food and Drug Administration today approved the first generic versions of Celebrex (celecoxib) capsules, a treatment for rheumatoid arthritis, osteoarthritis, short-term (acute) pain, and other conditions. (Source: Food and Drug Administration)
Source: Food and Drug Administration - May 30, 2014 Category: American Health Source Type: news
Celebrex cost high in United States, low in Canada
Read the full story on MD Consult:
Celebrex cost high in United States, low in Canada (Source: MD Consult: News: Top Stories)
Source: MD Consult: News: Top Stories - May 14, 2014 Category: Journals (General) Source Type: news
FyMed Announces Top-Line Results Demonstrating Superiority of FY103B...
FyMed, Inc. today announced top-line results from studies of FY103B, its new NSAID candidate, which demonstrated significant superiority over celecoxib in terms of efficacy and safety.(PRWeb April 24, 2014)Read the full story at http://www.prweb.com/releases/2014/04/prweb11785126.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 25, 2014 Category: Pharmaceuticals Source Type: news
Pfizer To Appeal Court Decision On Celebrex Reissue Patent
Pfizer Inc. announced it will appeal the court decision regarding blockbuster painkiller Celebrex reissue patent. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - March 13, 2014 Category: Pharmaceuticals Source Type: news
U.S. Court Cuts 18 Months Off Pfizer Celebrex Patent Life
Federal court has invalidated a patent that would have offered Pfizer an additional 18 months of U.S. exclusivity for its blockbuster painkiller, Celebrex. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - March 13, 2014 Category: Pharmaceuticals Source Type: news
Pfizer Says Court Invalidates Celebrex Patent
Pfizer said a federal court has invalidated a reissue patent that would have offered an additional 18 months of U.S. exclusivity — and monopoly sales — to its blockbuster painkiller Celebrex. (Source: WSJ.com: Health)
Source: WSJ.com: Health - March 13, 2014 Category: Pharmaceuticals Tags: PAID Source Type: news
Here's How Big Pfizer Is
Earlier today Pfizer stock was halted by the New York Stock Exchange. The reason: A Virginia court had invalidated the patent on the company's drug Celebrex, which is expected to generate $2.1 billion in annual sales in 2014. In the worst case, generics of Celebrex could be available starting May 30, says Mark Schoenebaum at ISI Group, dropping earnings per share by $0.12 cents. Which sounds disastrous. Celebrex was supposed to last until early 2016, meaning that Pfizer is losing about $3 billion in revenues. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - March 12, 2014 Category: Pharmaceuticals Authors: Matthew Herper Source Type: news
Pfizer says U.S. court invalidates Celebrex patent; generics loom
(Reuters) - A U.S. court ruled invalid a patent covering Pfizer Inc's blockbuster Celebrex painkiller, the drugmaker said, giving generic rivals an earlier U.S. entry that analysts estimated could cost the company $3 billion in revenue by the end of 2015. (Source: Reuters: Health)
Source: Reuters: Health - March 12, 2014 Category: Consumer Health News Tags: healthNews Source Type: news
